Intra-Cellular Therapies' GAAP loss for 3 months of 2022 was $72.119 million, up 36.7% from $52.74 million in the prior year. Revenue increased 2.2-fold to $34.996 million from $15.878 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept